Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Aeglea Biothera (NQ: AGLE )

7.470 USD UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 17, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 7.470
Bid (Size) 7.470 (4)
Ask (Size) 7.490 (7)
Prev. Close 7.470
Today's Range 7.470 - 7.470
52wk Range 6.430 - 11.38
Shares Outstanding 49,023,640
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Aeglea BioTherapeutics Reports First Quarter 2021 Financial Results and Corporate Highlights
Completed Patient Randomization for Phase 3 PEACE Clinical Trial; Topline Data Expected in Q4 
From PR Newswire
Aeglea BioTherapeutics Launches THINK ARGININE™, a Disease Education Initiative to Improve Awareness and Diagnosis of Arginase 1 Deficiency
Includes Sponsored Diagnostic Testing and Services for Patients with Suspected Arginase 1 Deficiency 
From PR Newswire

Performance

YTD
-12.73%
-12.73%
1 Month
+0.40%
+0.40%
3 Month
+2.75%
+2.75%
6 Month
-23.15%
-23.15%
1 Year
-2.61%
-2.61%

More News

Read More
Aeglea BioTherapeutics Completes Patient Randomization for PEACE, its Pivotal Phase 3 Clinical Trial of Pegzilarginase for the Treatment of Arginase 1 Deficiency
From PR Newswire
Aeglea BioTherapeutics to Participate in Two Virtual Investor Conferences in April 2021
From PR Newswire
Aeglea BioTherapeutics and Immedica Announce Commercialization Agreement for Pegzilarginase for the Treatment of Arginase 1 Deficiency in Europe and Middle East
From PR Newswire
Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights
From PR Newswire
Aeglea BioTherapeutics Appoints Sara Brownstein to Board of Directors
From PR Newswire
Aeglea BioTherapeutics Announces Transition of Chief Financial Officer
From PR Newswire
Aeglea BioTherapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
From PR Newswire
Aeglea BioTherapeutics Appoints Alison Lawton to Board of Directors
From PR Newswire
Aeglea BioTherapeutics Receives FDA Rare Pediatric Disease Designation for ACN00177 for the Treatment of Homocystinuria
From PR Newswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.